

REMARKS

Applicants have canceled claims 1-2, 4-7, 16-17 and 24. The cancellation of this and any other subject matter is without waiver of applicants' rights to file divisional or continuing applications directed to this subject matter and claiming priority to this application under 35 U.S.C. § 120.

Applicants have amended claim 3 to delete reference to subject matter allowed in this application's parent. As amended, claim 3 recites only the (Ie) and (Ig) genera. Support for the amended genera appears throughout the specification as originally filed, e.g., pages 35-50. Tables 3 and 4 together disclose a large number of exemplary compounds that fall within the scope of amended claim 3. Further, the specification provides a large number of embodiments of Q₃ and Q₂ (see, e.g., pages 12-14 for examples of preferred Q₂ embodiments and page 36 for examples of preferred Q₃ embodiments. Accordingly, it is clear that applicants were in full possession of the claimed genera as well as the individual species at the time of filing (as well as the compositions and methods of treatment based on those compounds), as required by 35 U.S.C. § 112, first paragraph.

Applicants have amended claims 8, 11-14, and 25 to delete reference to canceled claims.

Applicants have amended claim 9 to correct certain structures in which the double bond of an imidazole ring was inadvertently omitted. Support for this amendment appears, e.g., in the specification as originally filed at page 32, Table 2, which discloses compound 123, a specific inhibitor having an imidazole moiety.

Applicants have amended claims 18 and 21 to correct inadvertent typographical errors.

Application No.: Not Yet Assigned
Amendment dated July 17, 2003
Preliminary Amendment of July 17, 2003

Applicants have amended claims 22 and 23 to recite compound structures.

Support for this amendment appears throughout the specification as originally filed (see, e.g., page 35, lines 1-5 and Tables 3-4 on pages 40-50).


Applicants have amended claim 26 to recite viral diseases, reperfusion/ischemia in myocardial ischemia, and renal ischemia. Support for this amendment appears, e.g., in claims 32 and 34 as originally filed.

None of these amendments add new matter. Their entry is requested.

Conclusion

Applicants request that the amendments herewith be entered, the accompanying arguments be considered, and the claims be allowed to pass to issue.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Kristin M. Joslyn (Reg. No. 47,692)
Agent for Applicants
FISH & NEAVE (Customer No. 1473)
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090